Literature DB >> 28346690

The benefits and limitations of cell-free DNA screening for 47, XXY (Klinefelter syndrome).

Carole Samango-Sprouse1,2, Colleen Keen3, Teresa Sadeghin3, Andrea Gropman4.   

Abstract

OBJECTIVE: The purpose of this paper is to provide an overview of the 47, XXY syndrome, which is the most commonly occurring X and Y chromosomal variation. This paper seeks to review what is currently known of noninvasive prenatal testing (NIPT) and 47, XXY and investigate potential risks and benefits of prenatal identification.
METHOD: A literature review of NIPT and 47, XXY was performed to identify limitations of current NIPT techniques.
RESULTS: As NIPT becomes an increasingly more routine procedure, prenatal findings of 47, XXY may increase. Awareness of this disorder and appropriate genetic counseling is necessary.
CONCLUSION: X and Y chromosomal variations will be identified through this screening, and the benefits and limitations to this finding need to be thoughtfully considered.
© 2017 John Wiley & Sons, Ltd. © 2017 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28346690     DOI: 10.1002/pd.5044

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  13 in total

Review 1.  A review of neurocognitive functioning and risk for psychopathology in sex chromosome trisomy (47,XXY, 47,XXX, 47, XYY).

Authors:  Sophie van Rijn
Journal:  Curr Opin Psychiatry       Date:  2019-03       Impact factor: 4.741

2.  Early Social Behavior in Young Children with Sex Chromosome Trisomies (XXX, XXY, XYY): Profiles of Observed Social Interactions and Social Impairments Associated with Autism Spectrum Disorder (ASD).

Authors:  Nienke Bouw; Hanna Swaab; Nicole Tartaglia; Lisa Cordeiro; Sophie van Rijn
Journal:  J Autism Dev Disord       Date:  2022-05-12

3.  Early symptoms of autism spectrum disorder (ASD) in 1-8 year old children with sex chromosome trisomies (XXX, XXY, XYY), and the predictive value of joint attention.

Authors:  Nienke Bouw; Hanna Swaab; Nicole Tartaglia; Rebecca L Wilson; Kim Van der Velde; Sophie van Rijn
Journal:  Eur Child Adolesc Psychiatry       Date:  2022-09-15       Impact factor: 5.349

4.  Prenatal phenotype of 47, XXY (Klinefelter syndrome).

Authors:  Kate Swanson; Juliet C Bishop; Huda B Al-Kouatly; Mona Makhamreh; Thomas Felton; Neeta L Vora; Teresa N Sparks; Angie C Jelin
Journal:  Prenat Diagn       Date:  2021-12-07       Impact factor: 3.242

5.  The behavioral profile of children aged 1-5 years with sex chromosome trisomy (47,XXX, 47,XXY, 47,XYY).

Authors:  Evelien Urbanus; Hanna Swaab; Nicole Tartaglia; Lisa Cordeiro; Sophie van Rijn
Journal:  Am J Med Genet C Semin Med Genet       Date:  2020-05-20       Impact factor: 3.908

Review 6.  Recent advances in managing and understanding Klinefelter syndrome.

Authors:  Priyanka Bearelly; Robert Oates
Journal:  F1000Res       Date:  2019-01-28

Review 7.  Update On The Clinical Perspectives And Care Of The Child With 47,XXY (Klinefelter Syndrome).

Authors:  Carole A Samango-Sprouse; Debra R Counts; Selena L Tran; Patricia C Lasutschinkow; Grace F Porter; Andrea L Gropman
Journal:  Appl Clin Genet       Date:  2019-10-23

Review 8.  A review of neurocognitive functioning of children with sex chromosome trisomies: Identifying targets for early intervention.

Authors:  Evelien Urbanus; Sophie van Rijn; Hanna Swaab
Journal:  Clin Genet       Date:  2019-07-11       Impact factor: 4.438

9.  Rapid screening for Klinefelter syndrome with a simple high-resolution melting assay: a multicenter study.

Authors:  Dong-Mei Fu; Yu-Lin Zhou; Jing Zhao; Ping Hu; Zheng-Feng Xu; Shi-Ming Lv; Jun-Jie Hu; Zhong-Min Xia; Qi-Wei Guo
Journal:  Asian J Androl       Date:  2018 Jul-Aug       Impact factor: 3.285

10.  Is genetic fatherhood within reach for all azoospermic Klinefelter men?

Authors:  Veerle Vloeberghs; Greta Verheyen; Samuel Santos-Ribeiro; Catherine Staessen; Willem Verpoest; Inge Gies; Herman Tournaye
Journal:  PLoS One       Date:  2018-07-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.